Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice T Shaw

Showing results (101-110 of 205) with videos related to

Pageof 21
Sort By:
ESMO Open|July 19, 2018
Patient-reported outcomes in a phase II, North American study of alectinib in patients with <i>ALK</i>-positive, crizotinib-resistant, non-small cell lung cancerSai-Hong Ignatius Ou, Mark A Socinski, Shirish Gadgeel, et al.
The New England Journal of Medicine|November 18, 2020
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung CancerAlice T Shaw, Todd M Bauer, Filippo de Marinis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung CancerJessica J Lin, Elizabeth Kennedy, Lecia V Sequist, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2022
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancerJulien Mazieres, Laura Iadeluca, Alice T Shaw, et al.
Future Oncology (London, England)|September 29, 2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancerBenjamin J Solomon, Todd M Bauer, Filippo de Marinis, et al.
British Journal of Cancer|November 18, 2017
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLCShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2017
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung CancerJessica J Lin, Lauren L Ritterhouse, Siraj M Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and CeritinibJustin F Gainor, Daniel S W Tan, Tomasso De Pas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2018
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung CancerIbiayi Dagogo-Jack, Pablo Martinez, Beow Y Yeap, et al.
Cancer Medicine|March 11, 2015
Complex renal cysts associated with crizotinib treatmentPatrick Schnell, Cynthia H Bartlett, Benjamin J Solomon, et al.
Pageof 21

Showing results (101-110 of 205) with videos related to

Sort By:
Pageof 21
ESMO Open|July 19, 2018
Patient-reported outcomes in a phase II, North American study of alectinib in patients with <i>ALK</i>-positive, crizotinib-resistant, non-small cell lung cancerSai-Hong Ignatius Ou, Mark A Socinski, Shirish Gadgeel, et al.
The New England Journal of Medicine|November 18, 2020
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung CancerAlice T Shaw, Todd M Bauer, Filippo de Marinis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung CancerJessica J Lin, Elizabeth Kennedy, Lecia V Sequist, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2022
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancerJulien Mazieres, Laura Iadeluca, Alice T Shaw, et al.
Future Oncology (London, England)|September 29, 2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancerBenjamin J Solomon, Todd M Bauer, Filippo de Marinis, et al.
British Journal of Cancer|November 18, 2017
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLCShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2017
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung CancerJessica J Lin, Lauren L Ritterhouse, Siraj M Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and CeritinibJustin F Gainor, Daniel S W Tan, Tomasso De Pas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2018
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung CancerIbiayi Dagogo-Jack, Pablo Martinez, Beow Y Yeap, et al.
Cancer Medicine|March 11, 2015
Complex renal cysts associated with crizotinib treatmentPatrick Schnell, Cynthia H Bartlett, Benjamin J Solomon, et al.
Pageof 21